Abbott India witnessed a 9% surge in its shares during morning trading on February 2 after announcing robust earnings for the December quarter. The company reported a net profit of Rs 311 crore in Q3, marking a 26% YoY increase. Despite the adverse impact of including key drugs in the government’s essential medicines list, which imposes price caps, revenue showed a nearly 9% rise to Rs 1,437 crore. EBITDA also increased by 24.2% to Rs 387.6 crore. Abbott India’s shares traded at Rs 28,100 on the NSE at 11:16 am, and the company’s strong quarterly performance resulted in significantly increased trading volumes, with 70,000 shares changing hands compared to the one-month daily average of 25,000 shares. The operational performance also reflected improvement, with the EBITDA margin expanding to 27%, up from 23.6% in the same quarter of the previous fiscal year.
